• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Gabapentin Enacarbil XR Efficacy Less Than Expected for AUD

Gabapentin Enacarbil XR Efficacy Less Than Expected for AUD

August 1, 2019
Thomas Jordan, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Falk DE et al, Alcohol Clin Exp Res 2019;43(1):158–169

Gabapentin enacarbil extended-release (GE-XR) (Horizant) is an extended-release version of gabapentin. GE-XR is a prodrug, meaning that once ingested it is metabolized into gabapentin. It is currently approved for treatment of postherpetic neuralgia and restless legs syndrome. It differs from the immediate-release version in dosing (twice a day for the GE-XR, as opposed to three times a day) and has less variable blood levels. Several previous studies showed that IR gabapentin may be helpful for reducing withdrawal symptoms and promoting abstinence in alcohol use disorder (AUD) (Anton RF et al, Am J Psychiatry 2011;168(7):709–717; Mason BJ et al, JAMA Intern Med 2014;174(1):70–77). Since an extended release version might be easier to prescribe and increase adherence, researchers tested this XR formulation for AUD.

This randomized, double-blind, placebo-controlled trial assigned 346 adults with moderate AUD to two groups: the treatment group (n = 173) received GE-XR tablets titrated to 600 mg twice daily, whereas the control group (also n = 173) received identical placebo tablets. Moderate AUD was defined as ingestion of at least 21 standard drinks per week for women and at least 28 standard drinks per week for men (1 standard drink = 0.6 oz of pure alcohol). Participants were not currently using any other substances and were not diagnosed with a major psychiatric disorder. The trial lasted 26 weeks.

The primary outcome was change in the percentage of subjects with no heavy drinking days (defined as 4 or more drinks (women) or 5 or more drinks (men) per drinking day). There were several secondary outcomes, such as percentage of heavy drinking days, percentage of days abstinent, and others. For the primary outcome and all secondary outcomes, no statistical advantage was seen between the GE-XR group and placebo. Patients taking GE-XR actually did significantly worse than the placebo group in two of the secondary outcomes: average number of DSM-5 AUD criteria (3.4 vs 2.8, p = 0.046) and depressive symptoms on the Beck Depression Inventory-II (6.5 vs 5.2, p = 0.046).

For the safety assessment, patients in the GE-XR group reported significantly more fatigue (25.9%), somnolence (17.6%), and tremor (5.9%) than the placebo group. There were also more patients reporting suicidal ideation in the GE-XR group (7 vs 1, but just below significance level at p = 0.067).

CATR’s Take
This study had a strong design, adequate sample size, and a basis for success in the previous positive trials of IR gabapentin (Mason BJ et al, JAMA Intern Med 2014;174(1):70–77). However, GE-XR didn’t show any positive outcomes and even had worse outcomes for AUD and depressive symptoms. Negative findings may have potentially been due to the dosing used in this trial or altered bioavailability of the XR prodrug formulation in an AUD population. Regardless, GE-XR at the dose studied in this trial can’t be recommended for treating AUD at this time.
Addiction Treatment
KEYWORDS addiction addiction-treatment alcohol alcohol-use-disorder alcoholism clinical-practice extended-release medication novel-medications pharmacology psychopharmacology research-update
Thomas Jordan, MD

Vyvanse for Sluggish Cognitive Tempo in ADHD

More from this author
www.thecarlatreport.com
Issue Date: August 1, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Legal Issues in Addiction Medicine, CATR, July/August 2019
Gabapentin Enacarbil XR Efficacy Less Than Expected for AUD
Can Buprenorphine Improve PTSD Symptoms?
Opioid Use Disorder: Is There an App for That?
New Generic Versions of Naloxone
Treating Addiction in Patients Transitioning to/from Incarceration
Primer: Confidentiality in Addiction Treatment
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.